Skip to content
OpenCapital
Get started

Lantheus Holdings LNTH US — Revenue

Similar metrics at other companies

PTC Therapeutics logo
PTCTUS — Revenue
$136.52M+186%
TEC
TECHUS — Revenue
$167.48M-7.9%
Armstrong World Industries logo
AWIUS — Revenue
$382.9M+12.8%
Henry Schein logo
HSICUS — Revenue
$2.27B+3.1%
NOVA, Inc. logo
NOVUS — Revenue
$749.5M+0.5%
Zimmer Biomet Holdings logo
ZBHUS — Revenue
$1.21B+8.6%

Other financials

Income statement

See full
Revenue$377.3M+1.2%
Gross profit$230.9M-2.9%
Operating income$81.3M-20.3%
Net income$118.4M+62.3%
EPS (diluted)$1.80+76.5%

Balance sheet

See full
Cash & equivalents$500.3M-46.8%
Total debt$627.9M+1.8%
Total equity$1.2B+4.1%
Total assets$2.3B+14.2%

Cash flow

See full
Operating cash flow$125.1M+16.3%
CapEx$3.2M-63.0%
Free cash flow$121.9M+23.3%

Valuation

See full
Market cap$6.76B-26.3%
Enterprise value$6.89B-20.5%
P/E24.2×-10.2×
P/S4.4×-1.6×

Profitability

See full
Gross margin60.5%-3.6pp
Operating margin18.8%-10.7pp
Net margin18%+0.7pp
FCF margin24.4%-6.4pp

Returns & leverage

See full
Return on equity23.5%-1.7pp
Debt / equity0.5×0.0×
Current ratio2.8×-2.9×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Lantheus Holdings’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lantheus Holdings's us — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lantheus Holdings's US — revenue?
Lantheus Holdings (LNTH) reported US — revenue of $354.43M in Q1 2026.
How has Lantheus Holdings's US — revenue changed year-over-year?
Lantheus Holdings's US — revenue decreased by 0.9% year-over-year, from $357.76M to $354.43M.
What does US — revenue mean?
This metric represents the total gross revenue generated from the sale of diagnostic products and services within the United States geographic segment, excluding any sales-based taxes collected from customers. It serves as a primary indicator of the company's market penetration and commercial success in its core domestic healthcare market. Growth in this figure reflects the effective adoption of the company's precision diagnostics and radiopharmaceutical oncology portfolios by domestic healthcare providers.